Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients

A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adver...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1995-04, Vol.13 (6), p.593-596
Main Authors: Wilde, Henry, Glueck, Reinhard, Khawplod, Pakamatz, Cryz, Stanley J., Tantawichien, Terapong, Thipkong, Penmas, Chomchey, Pranee, Prakongsri, Sompop, Benjavongkulchai, Maneerat, Sumboonanondha, Aree, Samranwetaya, Ponsri, Supakorn, Kantorn, Sitprija, Visith
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies, Viral - blood
Biological and medical sciences
Bites and Stings
Child
Child, Preschool
Diploidy
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Human Diploid Cell Rabies Vaccine
Humans
Male
Microbiology
Middle Aged
Prospective Studies
Rabies - epidemiology
Rabies - prevention & control
rabies vaccine
rabies vaccine efficacy
rabies vaccine reactions
Rabies Vaccines - therapeutic use
serum sickness
Thailand
Thailand - epidemiology
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and efficacy in 100 severely rabies-exposed Thais. All patients also received human rabies immune globulin and vaccine was administered using the conventional 5-dose intramuscular schedule of one dose on days 0, 3, 7, 14 and 28. One hundred percent of a subgroup of 40 subjects, where blood had been collected, had neutralizing antibodies greater than 0.5 IU ml −1 on days 28 and 90 and all had detectable titers on days 7, 14, 28, 90, 180 and 360. All patients could be followed for at least 1 year and remained well. No significant side-effects from this vaccine were noted.
ISSN:0264-410X
1873-2518
DOI:10.1016/0264-410X(94)00049-S